
CHO-K1 Rat Chemerin 2 β-Arrestin Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-A-0051F | Inquiry |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Chemokine-like receptor 2 (CMKLR2) is a G protein-coupled receptor primarily expressed in immune cells like monocytes and macrophages. Activated by ligands such as Resolvin E1, its core function is to promote the resolution of inflammation and tissue repair, making it a potential target for treating inflammatory diseases.
ScreeningBio’s CHO-K1/Rat Chemerin 2 β-arrestin cell line is an ideal tool for studying GPCR/β-arrestin interactions. In this system, the GPCR C-terminus is fused to a smallBiT tag, and the β2-arrestin N-terminus is fused to a largeBiT tag. Upon receptor activation, GPCR/β-arrestin interaction brings the two fragments together to reconstitute an active NanoLuc enzyme, which can be quantified using the NanoBiT substrate. This cell line is designed to evaluate a compound’s ability to activate the β-arrestin signaling pathway.
Product Specifications
Target Type | GPCR |
Species | Rat |
HGNC Symbol | CMKLR2 |
Accession Number | NM_012961 (Rn) |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![CHO-K1/Rat Chemerin 2 β-arrestin Agonist Assay. CHO-K1/Rat Chemerin 2 β-arrestin cells were treated with the reference agonist. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 /IC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/cbf7de_02d4fe19a0d049e89168efc2e88d28f2~mv2.png/v1/fill/w_75,h_75,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/cbf7de_02d4fe19a0d049e89168efc2e88d28f2~mv2.png)
Target Background
Chemokine-like receptor 2 (CMKLR2) is a G protein-coupled receptor primarily expressed in immune cells like monocytes and macrophages. Activated by ligands such as Resolvin E1, its core function is to promote the resolution of inflammation and tissue repair, making it a potential target for treating inflammatory diseases.
